bluebird bio (BLUE)

74.04 +0.28 (0.38%)

Chart
Today 6M 1Y 5Y

Latest Headlines

Form 8-K bluebird bio, Inc. For: Nov 12 November 12, 2019 7:38 AM - SEC Filing bluebird bio and Forty Seven Announce a Research Collaboration to Study an All Antibody Conditioning Regimen for Use in Combination with Autologous Lentiviral Vector Hematopoietic Stem Cell Gene Thera November 12, 2019 7:00 AM - BizWire Form SC 13G/A bluebird bio, Inc. Filed by: Capital World Investors November 8, 2019 12:28 PM - SEC Filing Form 4 bluebird bio, Inc. For: Nov 05 Filed by: Gregory Philip D November 7, 2019 4:15 PM - SEC Filing bluebird bio (BLUE) option implied volatility flat into American Society of Hematology (ASH) Annual Meeting November 7, 2019 5:14 AM - StreetInsider Form 8-K bluebird bio, Inc. For: Nov 06 November 6, 2019 9:11 AM - SEC Filing bluebird bio (BLUE) to Present New Data from Gene and Cell Therapy Programs at ASH November 6, 2019 9:01 AM - StreetInsider bluebird bio to Present New Data from Gene and Cell Therapy Programs at 61st American Society of Hematology Annual Meeting and Exposition November 6, 2019 9:00 AM - BizWire Form SC 13G bluebird bio, Inc. Filed by: BAILLIE GIFFORD & CO November 5, 2019 10:16 AM - SEC Filing Wedbush Upgrades bluebird bio (BLUE) to Outperform November 4, 2019 6:12 AM - StreetInsider bluebird bio (BLUE) PT Lowered to $100 at Morgan Stanley November 1, 2019 8:46 AM - StreetInsider bluebird bio (BLUE) PT Lowered to $96 at Stifel November 1, 2019 7:55 AM - StreetInsider bluebird bio (BLUE) PT Lowered to $85 at Piper Jaffray November 1, 2019 7:10 AM - StreetInsider bluebird bio (BLUE) PT Lowered to $100 at Morgan Stanley November 1, 2019 7:00 AM - StreetInsider Form 10-Q bluebird bio, Inc. For: Sep 30 October 31, 2019 4:49 PM - SEC Filing Form 8-K bluebird bio, Inc. For: Oct 31 October 31, 2019 4:18 PM - SEC Filing bluebird bio Reports Third Quarter 2019 Financial Results and Highlights Operational Progress October 31, 2019 4:05 PM - BizWire Form 8-K bluebird bio, Inc. For: Oct 22 October 23, 2019 5:04 PM - SEC Filing bluebird bio Announces Transition of Chief Strategy Officer Jeffrey T. Walsh October 23, 2019 4:30 PM - BizWire Form 8-K bluebird bio, Inc. For: Oct 22 October 22, 2019 8:06 AM - SEC Filing bluebird bio (BLUE) Announces EMA Approves Refined Commercial Manufacturing Specifications for ZYNTEGLO October 22, 2019 7:34 AM - StreetInsider European Medicines Agency Approves Refined Commercial Manufacturing Specifications for ZYNTEGLO™ October 22, 2019 7:30 AM - BizWire bluebird bio (BLUE) PT Lowered to $104 at Morgan Stanley October 11, 2019 8:45 AM - StreetInsider Form 4 bluebird bio, Inc. For: Oct 07 Filed by: Gregory Philip D October 9, 2019 4:15 PM - SEC Filing Form 8-K bluebird bio, Inc. For: Oct 09 October 9, 2019 8:23 AM - SEC Filing bluebird bio (BLUE), Novo Nordisk (NVO) Enter into Research Agreement to Develop in vivo Genome Editing Candidates for Haemophilia and Other Severe Genetic Diseases October 9, 2019 8:03 AM - StreetInsider bluebird bio and Novo Nordisk Enter into Research Agreement to Develop in vivo Genome Editing Candidates for Haemophilia and Other Severe Genetic Diseases October 9, 2019 8:00 AM - BizWire UPDATE: Stifel Starts bluebird bio (BLUE) at Hold September 30, 2019 4:10 PM - StreetInsider Form 4 bluebird bio, Inc. For: Sep 25 Filed by: Sellers William R. September 27, 2019 4:10 PM - SEC Filing Form 3 bluebird bio, Inc. For: Sep 25 Filed by: Sellers William R. September 27, 2019 4:08 PM - SEC Filing Form 8-K bluebird bio, Inc. For: Sep 25 September 27, 2019 8:01 AM - SEC Filing bluebird bio (BLUE) Names William R. Sellers M.D. to Board September 27, 2019 7:02 AM - StreetInsider bluebird bio Appoints William R. Sellers, M.D. to Board of Directors September 27, 2019 7:00 AM - BizWire bluebird bio (BLUE) ALD-103 Data Analysis - William Blair September 19, 2019 8:45 AM - StreetInsider Form 8-K bluebird bio, Inc. For: Sep 18 September 18, 2019 4:24 PM - SEC Filing bluebird bio (BLUE) Reports Updated Data from Phase 2/3 Clinical Study of Lenti-D Gene Therapy for CALD at EPNS 2019 Meetings September 18, 2019 9:26 AM - StreetInsider bluebird bio Presents Updated Data from Phase 2/3 Clinical Study of Lenti-D™ Gene Therapy for Cerebral Adrenoleukodystrophy (CALD) at the 13th European Pediatric Neurology Society (EPNS) Congress September 18, 2019 9:25 AM - BizWire Form 4 bluebird bio, Inc. For: Sep 09 Filed by: Davidson David September 11, 2019 4:29 PM - SEC Filing Form 4 bluebird bio, Inc. For: Sep 05 Filed by: Gregory Philip D September 9, 2019 4:54 PM - SEC Filing bluebird bio to Present Data from Clinical Development Program of Lenti-DTM Gene Therapy for Cerebral Adrenoleukodystrophy (CALD) at the 13th European Pediatric Neurology Society (EPNS) Congress September 3, 2019 7:30 AM - BizWire bluebird bio Announces Investor Events in September August 22, 2019 4:05 PM - BizWire Form 4 bluebird bio, Inc. For: Aug 20 Filed by: Walsh Jeffrey T. August 21, 2019 4:06 PM - SEC Filing Full Article List